Please assess the completion status of the following clinical trial:

Trial Title: Defining Strategies for Improving Endothelial and Fibrinolytic Dysfunction in Obesity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or females between the ages of 18 to 65 years of age.~* Documented diagnosis for the metabolic syndrome:~* Subjects with hypertension (SP\>130mmHg)~* Subjects with central obesity (females waist \>35; males waist \>40)~* Subjects with dyslipidemia (HDL \<40mg/dl, triglycerides \> 150 mg/dl)~* Subjects who are insulin resistance (fasting glucose \>100mg/dl)~Exclusion Criteria:~* Subjects who smoke~* Women who are pregnant (confirmed by urine beta-HCG).~* Women who are breast feeding~* Subjects with documentation of the following health risk:~  * Subjects with serum creatinine \>2.0 mg/dl (males), \>1.8 mg/dl (females)~ * Subjects whose creatinine clearance \< 50 mls/min~ * Subjects with serum potassium \>5.5mEql~ * Subjects with Type 2 diabetes with microalbuminuria (spot urine protein/creatinine ration \>0.2)~* Subjects who are currently taking the following medications:~* Warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Treatment A (Type: ACTIVE_COMPARATOR): Eplerenone (study drug)
- Treatment B (Type: ACTIVE_COMPARATOR): Ramipril

Based on this trial design, predict the completion outcome and termination type (if applicable).